MACK Summary

  1. NASDAQ
  2. >
  3. MACK
TickerMACK
DescriptionMERRIMACK PHARMACEUTICALS INC
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts that is entitled to receive up to $450.0 million in contingent milestone payments related to its sale of ONIVYDE® to Ipsen S.A. in April 2017. These milestone payments would be payable by Ipsen upon approval by the U.S. Food and Drug Administration ('FDA') of ONIVYDE® for certain additional clinical indications. ONIVYDE® is already approved by the FDA in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. This existing approval is unrelated to any future potential milestone payments. Merrimack's agreement with Ipsen does not require Ipsen to provide Merrimack with any information on the progress of ONIVYDE® clinical trials that is not publicly available. Merrimack is also entitled to receive up to $54.5 million in contingent milestone payments related to its sale of anti-HER3 programs to Elevation Oncology (formerly 14ner Oncology, Inc.) in July 2019. The Company is seeking potential acquirers for its remaining preclinical assets.
ExchangeNASDAQ
TypeStock
SectorHealthcare
Next Earnings DateAugust 6th, 2021
IV170.009289%
IV Percentile96th
IV Rank46.55%
IV Skew27.153691
IV Skew Percentile69th
IV Skew SentimentBearish
Option Volume139
Volume13,538
Price$5.23
Previous Close$5.18
52-Week High$9.45
52-Week Low$3.239
50-Day Moving Avg.$6.22
200-Day Moving Avg.$6.70
10-Day Avg. Volume27,729
20-Day Avg. Volume24,912
30-Day Avg. Volume25,331
3-Month Avg. Volume24,429
EPS-$0.30
Outstanding Shares13,410,243
Market Capitalization$71,342,500
CurrencyUSD
UpdatedAugust 4th, 2021